Monday 6-17-2014 Abbvie Inc. Common Stock (ABBV) $
Post# of 194
Posted On: 06/17/2014 9:02:29 PM
Monday 6-17-2014 Abbvie Inc. Common Stock (ABBV) $ABBV opened at 54.49 hitting the high price of 54.54 and a day low of 53.85 with a total volume of 3,385,676. ABBV had a previous close of 54.00 and has been seeing an average volume of 4,299,230.
Overall Average: 40% Buy
Recent stock forum discussions about ABBV http://investorshangout.com/search?q=ABBV&...mp;yt0=Go!
Is This Gilead's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Tue Jun 17, 4:30PM CDT
It's not often that big name biotechs double their earnings year over year. Yet that's exactly what Gilead Sciences did in the first quarter of 2014 after posting record sales for its new hepatitis C drug Sovaldi. Sovaldi raked in a reported... (full story)
GW Pharma Up On Positive Data For Epilepsy Drug
at Investor's Business Daily - Tue Jun 17, 3:20PM CDT
British biotech GW Pharmaceuticals (GWPH) Tuesday reported positive safety and efficacy data from physicians treating epileptics with its drug Epidiolex, sending the stock up 16% to 89.82 on the stock market today . But shares gave up some of those... (full story)
Why This "Worst Deal" Could Work
Brian Wilson, The Motley Fool - Motley Fool - Tue Jun 17, 9:42AM CDT
Recently, the pharmaceutical giant Merck has been receiving a bit of heat from commentators who believe that the company offered way too much money for the hepatitis c therapeutics developer Idenix Pharmaceuticals last week. Although the... (full story)
2 Exciting Developments for Biogen Idec Inc.
Cheryl Swanson, The Motley Fool - Motley Fool - Tue Jun 17, 8:02AM CDT
Biogen , which just got nod from the FDA for its potential blockbuster hemophilia drug Eloctate last week, has also now cleared a major hurdle for a drug in its multiple sclerosis franchise. Joint developers Biogen and AbbVie announced Monday... (full story)
European Medicines Agency Validates Marketing Authorization Applications for AbbVie's Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C
PR Newswire Europe - Tue Jun 17, 4:19AM CDT
AbbVie announced today that the Marketing Authorization Applications (MAAs) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection have been validated and are under accelerated assessment by the European Medicines Agency (EMA). (full story)
AbbVie Gets Priority Review from FDA for HCV Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 12:50PM CDT
AbbVie's (ABBV) experimental hepatitis C virus treatment could gain approval early in the fourth quarter of 2014. (full story)
Better Stock Today Challenge: Bank of America Corp vs. AbbVie
David Hanson and David Williamson, The Motley Fool - Motley Fool - Mon Jun 16, 11:22AM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner. Bank of America takes on AbbVie for this... (full story)
Gilead's HCV Combination Therapy Data Looks Promising - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 10:40AM CDT
Gilead Sciences (GILD) announced encouraging results from a phase III study on its HCV combination therapy of ledipasvir and Sovaldi . (full story)
Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis
Business Wire - Mon Jun 16, 6:30AM CDT
--a^' Positive Results Set Stage for Regulatory Filings - (full story)
Memory Impairment - Pipeline Review, H1 2014
M2 - Mon Jun 16, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vb8j8m/memory_impairment) has announced the addition of the "Memory Impairment - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Memory Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Memory Impairment and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Memory Impairment - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Memory Impairment and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Suven Life Sciences Ltd. - M et P Pharma AG - Dart NeuroScience LLC - Omeros Corporation - Sunovion Pharmaceuticals Inc. - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/vb...impairment (full story)
AbbVie's NDA for investigational, all-oral, interferon-free regimen for treating hepatitis C virus accepted by the US FDA for priority review
M2 - Mon Jun 16, 3:59AM CDT
Biopharmaceutical company AbbVie (NYSE:ABBV) disclosed on Friday that its New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for treating hepatitis C virus (HCV) infection has been accepted by the US Food and Drug Administration (FDA) for review. (full story)
Why Shorts Are Betting Against Enanta Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Sun Jun 15, 5:00PM CDT
Short interest is often a key metric that investors can use to gain some insight into how the Street feels about a particular stock. And when short interest picks up dramatically, it's generally a good idea to know why. Shares of little-known ... (full story)
Better Stock Today: Ford vs. AbbVie
Frank Thomas and David Williamson, The Motley Fool - Motley Fool - Sun Jun 15, 11:00AM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other, and you, the reader, will determine the winner. Ford takes on AbbVie for this first... (full story)
U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C
PR Newswire - Fri Jun 13, 2:34PM CDT
AbbVie (NYSE: ABBV) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review. (full story)
Could This Buyout Go Down As One of the Worst Deals Ever?
Sean Williams, The Motley Fool - Motley Fool - Fri Jun 13, 2:15PM CDT
You certainly don't have to look far these days to see that merger and acquisition activity is picking up across a number of sectors. Investors and Wall Street analysts love to see M&A activity because it signals two things. First, it points to... (full story)
How the U.S. Government Makes Money on Cannabis
at The Street - Fri Jun 13, 10:30AM CDT
The U.S. government holds a patent on cannabinoids and has collected money for licensing the patent. It could eventually collect thousands of dollars in royalties. (full story)
Equity Coverage on Pharma Industry -- Research on AbbVie, AcelRx Pharma, Bristol-Myers Squibb, and GW Pharma
PR Newswire - Fri Jun 13, 6:10AM CDT
The trading session on Thursday, June 12, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,734.19, down 0.65% and the NASDAQ Composite closed at 4,297.63, down 0.79%. The S&P 500 finished the day 0.71% lower at 1,930.11. The losses were broad based as eight out of the ten sectors finished on a negative note. The S&P 500 Health Care Sector Index finished the day 0.56% lower at 688.58, while the index has gained 1.97% in the previous one month. Investor-Edge has initiated coverage on the following equities: AbbVie Inc. (NYSE: ABBV), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), Bristol-Myers Squibb Co. (NYSE: BMY) and GW Pharmaceuticals PLC (NASDAQ: GWPH). Free technical research on ABBV, ACRX, BMY and GWPH can be downloaded upon signing up at: (full story)
Is Amgen's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Thu Jun 12, 4:30PM CDT
Amgen is one of the globe's biggest drug companies, and investors looking to sprinkle growth-oriented biotechnology companies into dividend portfolios often consider buying its shares. Big drug companies such as Amgen, AbbVie , and Johnson... (full story)
Expansions, New Leadership, Annual Award Winners, FDA Approvals, and Abstracts Presentations - Analyst Notes on AbbVie, Amgen, Regeneron Pharmaceuticals Inc, Valeant Pharmaceuticals and Lilly
PR Newswire - Thu Jun 12, 5:40AM CDT
Today, Analysts Review released its analysts' notes regarding AbbVie Inc. (NYSE: ABBV), Amgen, Inc. (NASDAQ: AMGN), Regeneron (NASDAQ: REGN), Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and Eli Lilly and Co (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3638-100free. (full story)
Overall Average: 40% Buy
Recent stock forum discussions about ABBV http://investorshangout.com/search?q=ABBV&...mp;yt0=Go!
Is This Gilead's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Tue Jun 17, 4:30PM CDT
It's not often that big name biotechs double their earnings year over year. Yet that's exactly what Gilead Sciences did in the first quarter of 2014 after posting record sales for its new hepatitis C drug Sovaldi. Sovaldi raked in a reported... (full story)
GW Pharma Up On Positive Data For Epilepsy Drug
at Investor's Business Daily - Tue Jun 17, 3:20PM CDT
British biotech GW Pharmaceuticals (GWPH) Tuesday reported positive safety and efficacy data from physicians treating epileptics with its drug Epidiolex, sending the stock up 16% to 89.82 on the stock market today . But shares gave up some of those... (full story)
Why This "Worst Deal" Could Work
Brian Wilson, The Motley Fool - Motley Fool - Tue Jun 17, 9:42AM CDT
Recently, the pharmaceutical giant Merck has been receiving a bit of heat from commentators who believe that the company offered way too much money for the hepatitis c therapeutics developer Idenix Pharmaceuticals last week. Although the... (full story)
2 Exciting Developments for Biogen Idec Inc.
Cheryl Swanson, The Motley Fool - Motley Fool - Tue Jun 17, 8:02AM CDT
Biogen , which just got nod from the FDA for its potential blockbuster hemophilia drug Eloctate last week, has also now cleared a major hurdle for a drug in its multiple sclerosis franchise. Joint developers Biogen and AbbVie announced Monday... (full story)
European Medicines Agency Validates Marketing Authorization Applications for AbbVie's Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C
PR Newswire Europe - Tue Jun 17, 4:19AM CDT
AbbVie announced today that the Marketing Authorization Applications (MAAs) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection have been validated and are under accelerated assessment by the European Medicines Agency (EMA). (full story)
AbbVie Gets Priority Review from FDA for HCV Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 12:50PM CDT
AbbVie's (ABBV) experimental hepatitis C virus treatment could gain approval early in the fourth quarter of 2014. (full story)
Better Stock Today Challenge: Bank of America Corp vs. AbbVie
David Hanson and David Williamson, The Motley Fool - Motley Fool - Mon Jun 16, 11:22AM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner. Bank of America takes on AbbVie for this... (full story)
Gilead's HCV Combination Therapy Data Looks Promising - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 10:40AM CDT
Gilead Sciences (GILD) announced encouraging results from a phase III study on its HCV combination therapy of ledipasvir and Sovaldi . (full story)
Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis
Business Wire - Mon Jun 16, 6:30AM CDT
--a^' Positive Results Set Stage for Regulatory Filings - (full story)
Memory Impairment - Pipeline Review, H1 2014
M2 - Mon Jun 16, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vb8j8m/memory_impairment) has announced the addition of the "Memory Impairment - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Memory Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Memory Impairment and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Memory Impairment - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Memory Impairment and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Suven Life Sciences Ltd. - M et P Pharma AG - Dart NeuroScience LLC - Omeros Corporation - Sunovion Pharmaceuticals Inc. - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/vb...impairment (full story)
AbbVie's NDA for investigational, all-oral, interferon-free regimen for treating hepatitis C virus accepted by the US FDA for priority review
M2 - Mon Jun 16, 3:59AM CDT
Biopharmaceutical company AbbVie (NYSE:ABBV) disclosed on Friday that its New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for treating hepatitis C virus (HCV) infection has been accepted by the US Food and Drug Administration (FDA) for review. (full story)
Why Shorts Are Betting Against Enanta Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Sun Jun 15, 5:00PM CDT
Short interest is often a key metric that investors can use to gain some insight into how the Street feels about a particular stock. And when short interest picks up dramatically, it's generally a good idea to know why. Shares of little-known ... (full story)
Better Stock Today: Ford vs. AbbVie
Frank Thomas and David Williamson, The Motley Fool - Motley Fool - Sun Jun 15, 11:00AM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other, and you, the reader, will determine the winner. Ford takes on AbbVie for this first... (full story)
U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C
PR Newswire - Fri Jun 13, 2:34PM CDT
AbbVie (NYSE: ABBV) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review. (full story)
Could This Buyout Go Down As One of the Worst Deals Ever?
Sean Williams, The Motley Fool - Motley Fool - Fri Jun 13, 2:15PM CDT
You certainly don't have to look far these days to see that merger and acquisition activity is picking up across a number of sectors. Investors and Wall Street analysts love to see M&A activity because it signals two things. First, it points to... (full story)
How the U.S. Government Makes Money on Cannabis
at The Street - Fri Jun 13, 10:30AM CDT
The U.S. government holds a patent on cannabinoids and has collected money for licensing the patent. It could eventually collect thousands of dollars in royalties. (full story)
Equity Coverage on Pharma Industry -- Research on AbbVie, AcelRx Pharma, Bristol-Myers Squibb, and GW Pharma
PR Newswire - Fri Jun 13, 6:10AM CDT
The trading session on Thursday, June 12, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,734.19, down 0.65% and the NASDAQ Composite closed at 4,297.63, down 0.79%. The S&P 500 finished the day 0.71% lower at 1,930.11. The losses were broad based as eight out of the ten sectors finished on a negative note. The S&P 500 Health Care Sector Index finished the day 0.56% lower at 688.58, while the index has gained 1.97% in the previous one month. Investor-Edge has initiated coverage on the following equities: AbbVie Inc. (NYSE: ABBV), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), Bristol-Myers Squibb Co. (NYSE: BMY) and GW Pharmaceuticals PLC (NASDAQ: GWPH). Free technical research on ABBV, ACRX, BMY and GWPH can be downloaded upon signing up at: (full story)
Is Amgen's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Thu Jun 12, 4:30PM CDT
Amgen is one of the globe's biggest drug companies, and investors looking to sprinkle growth-oriented biotechnology companies into dividend portfolios often consider buying its shares. Big drug companies such as Amgen, AbbVie , and Johnson... (full story)
Expansions, New Leadership, Annual Award Winners, FDA Approvals, and Abstracts Presentations - Analyst Notes on AbbVie, Amgen, Regeneron Pharmaceuticals Inc, Valeant Pharmaceuticals and Lilly
PR Newswire - Thu Jun 12, 5:40AM CDT
Today, Analysts Review released its analysts' notes regarding AbbVie Inc. (NYSE: ABBV), Amgen, Inc. (NASDAQ: AMGN), Regeneron (NASDAQ: REGN), Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and Eli Lilly and Co (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3638-100free. (full story)
(0)
(0)AbbVie Inc. (ABBV) Stock Research Links
Scroll down for more posts ▼